business
Adherex Technologies’ PEDMARK Push Targets Larger AYA Market After Record Quarter
Key takeaways
- Fennec Pharmaceuticals said PEDMARK is seeing stronger commercial traction, with first-quarter 2026 revenue reaching a record $15.1 million as the company expands its sales force and targets more than 5,400 U.S.
- Fennec highlighted international expansion and patent protection, including a European partnership with Norgine, plans for a Japan deal, and a U.S. settlement that keeps a generic challenger off the market until 2033.
- Fennec Pharmaceuticals (NASDAQ:FENC) executives outlined the company’s commercial strategy for PEDMARK, its sodium thiosulfate product used to prevent cisplatin-related hearing loss, during a fireside chat at the H.C.
Adherex Technologies’ PEDMARK Push Targets Larger AYA Market After Record Quarter Adherex Technologies logo Market Beat Sat, May 23, 2026 at 9:05 PM GMT+7 6 min read FENC Key Points Interested in Adherex Technologies Inc.? Here are five stocks we like better.
Fennec Pharmaceuticals said PEDMARK is seeing stronger commercial traction, with first-quarter 2026 revenue reaching a record $15.1 million as the company expands its sales force and targets more than 5,400 U.S. treatment sites.
The company is focusing on the adolescent and young adult (AYA) market, which management says is about 10 times larger than the pediatric market, and is also promoting home administration through its Fennec HEARS program.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop